RxDoctor Payments DataLook up a doctor →

Orlin Sergev

Endocrinology, Diabetes & Metabolism · Summerville, SCNPI 1003845207

Payments from drug & device makers

$29,376in general payments, 2019–2025

Across 515 payments — averaging $57.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$13K
  • Tandem Diabetes Care, Inc.$7K
  • AbbVie$907
  • Medtronic$871
  • Sanofi-aventis U.S. LLC$720
  • Lilly USA, LLC$633
  • plus $6K from 48 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer66$13,346
Tandem Diabetes Care, Inc.32$6,993
AbbVie44$907
Medtronic(2 entities)33$871
Sanofi-aventis U.S. LLC27$720
Lilly USA, LLC39$633
IBSA Pharma Inc.34$620
Xeris Pharmaceuticals, Inc.27$503
Insulet Corporation18$494
Amgen(2 entities)22$435
Abbott16$353
Novo Nordisk18$342
Radius Health, Inc.7$282
Amneal Pharmaceuticals LLC13$266
Corcept Therapeutics10$211
Antares Pharma, Inc.9$175
BETA Bionics, Inc.6$158
Ascendis Pharma Endocrinology Inc5$126
Nevro Corp.4$120
Recordati_rare_diseases_inc.4$120
Cequr Corporation3$118
Neurocrine Biosciences, Inc.4$98
AstraZeneca6$93
Zealand Pharma US, Inc.5$92
Madrigal Pharmaceuticals3$90
Renalytix AI, Inc.4$81
Verity Pharmaceuticals Inc.3$81
Kyowa Kirin, Inc.3$80
Mannkind Corporation2$75
Almatica Pharma LLC3$70
Tolmar, Inc.4$66
Valeritas, Inc.3$62
Ascensia Diabetes Care US Inc.2$61
Ultragenyx Pharmaceutical Inc.3$57
Shire North American Group Inc3$45
OPKO Pharmaceuticals, LLC2$41
Senseonics, Incorporated3$41
Dexcom, Inc.2$41
Boehringer Ingelheim2$39
Clarus Therapeutics Inc.3$36
Amarin Pharma, Inc.2$36
Novartis2$33
Intuity Medical Inc1$30
BD2$28
Johnson & Johnson1$26
Averitas Pharma Inc.1$25
Merck2$25
Astellas Pharma US Inc1$21
Alnylam Pharmaceuticals Inc.1$19
Sequel Med Tech, LLC1$19
Amryt Pharma Holdings Ltd1$18
Acerus Pharmaceuticals Corporation1$18
Endo Pharmaceuticals Inc.1$17
Currax Pharmaceuticals LLC1$15

How this compares

$29,376 in reported general payments places this provider in the 75th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

See all endocrinology, diabetes & metabolism providers in South Carolina →

Medicare billing

Part B allowed, 2024
$168,099
Medicare patients
379
Services billed
11,279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Summerville

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →